Medicine Efficacy and safety of neoadjuvant stereotactic body radiation therapy plus dalpiciclib and exemestane for hormone receptor-positive, HER2-negative breast cancer: A prospective pilot study ...

Disc Medicine received positive FDA feedback for its bitopertin NDA submission in Erythropoietic Protoporphyria, planned for October 2025.

Ad hoc announcement pursuant to Art. 53 LR At interim analysis, PSMAddition trial met its primary endpoint showing statistically significant and clinically meaningful benefit for Pluvicto™ plus ...

A phase 1 study of abemaciclib and niraparib as neoadjuvant therapy in hormone receptor positive and HER2 negative breast cancer.. If you have the appropriate software installed, you can download ...

Haters gonna hate. The good news is that you can use that anger to your advantage. Bill Farquharson explains in this week's Sales Tip.

New HER2-targeted regimens, including chemotherapy-free options, are needed for metastatic breast cancer. In an ongoing, two-part, phase 2a study, we assessed the safety and antitumour activity of ...

Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors plus endocrine therapy (ET) represents the standard first-line treatment for patients with hormone receptor–positive/human epidermal growth factor ...

Based on the FDA's feedback, Axsome plans to submit a supplemental NDA for AXS-05 in Alzheimer's disease agitation in third-quarter 2025.

Traditional circuits often suffer from significant peak current fluctuations due to sensitivity to temperature, process variations, and other conditions, leading to detection deviations that can ...

Palbociclib plus exemestane with a gonadotropin-releasing hormone agonist was not associated with longer overall survival than with capecitabine in premenopausal women with hormone receptor-positive, ...